abiraterone acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiandrogens	4176	154229-18-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: abiraterone acetate zytiga CB-7630 CB7630	Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 alpha-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone to their 17alpha-hydroxy derivatives by 17alpha-hydroxylase activity and 2) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17,20 lyase activity. DHEA and androstenedione are androgens and are precursors of testosterone. Inhibition of CYP17 by abiraterone can also result in increased mineralocorticoid production by the adrenals. Androgen sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumor. Abiraterone acetate decreased serum testosterone and other androgens in patients in the placebo-controlled clinical trial. It is not necessary to monitor the effect of abiraterone acetate on serum testosterone levels. Molecular weight: 391.56 Formula: C26H33NO2 CLOGP: 6.11 LIPINSKI: 1 HAC: 3 HDO: 0 TPSA: 39.19 ALOGS: -5.59 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

abiraterone acetate
zytiga
CB-7630
CB7630

Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 alpha-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone to their 17alpha-hydroxy derivatives by 17alpha-hydroxylase activity and 2) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17,20 lyase activity. DHEA and androstenedione are androgens and are precursors of testosterone. Inhibition of CYP17 by abiraterone can also result in increased mineralocorticoid production by the adrenals. Androgen sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumor. Abiraterone acetate decreased serum testosterone and other androgens in patients in the placebo-controlled clinical trial. It is not necessary to monitor the effect of abiraterone acetate on serum testosterone levels.

Molecular weight: 391.56
Formula: C26H33NO2
CLOGP: 6.11
LIPINSKI: 1
HAC: 3
HDO: 0
TPSA: 39.19
ALOGS: -5.59
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 5, 2011	EMA	Janssen-Cilag International N.V.
April 28, 2011	FDA	JANSSEN BIOTECH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Prostatic specific antigen increased	61.64	41.03	5	80	0	50605039

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	2126.76	15.85	2292	32925	339792	29199518
Prostatic specific antigen increased	2071.75	15.85	715	34502	11849	29527461
Disease progression	748.70	15.85	683	34534	81233	29458077
Therapy cessation	716.89	15.85	348	34869	14114	29525196
Hot flush	579.17	15.85	304	34913	14566	29524744
Hospitalisation	424.12	15.85	386	34831	45602	29493708
Hypokalaemia	423.65	15.85	401	34816	49802	29489508
Metastases to bone	372.90	15.85	198	35019	9700	29529610
Prostate cancer metastatic	350.96	15.85	153	35064	4813	29534497
Osteonecrosis of jaw	263.35	15.85	191	35026	16319	29522991
Fatigue	241.10	15.85	874	34343	315947	29223363
Prostate cancer	187.13	15.85	189	35028	25338	29513972
Malignant neoplasm progression	170.46	15.85	311	34906	73548	29465762
Product size issue	170.09	15.85	51	35166	518	29538792
Urinary tract infection	167.40	15.85	305	34912	72049	29467261
Product use complaint	152.39	15.85	53	35164	891	29538419
Hormone-refractory prostate cancer	144.19	15.85	46	35171	583	29538727
Hospice care	127.72	15.85	78	35139	4990	29534320
Toxicity to various agents	106.54	15.85	37	35180	173624	29365686
Adverse event	106.17	15.85	110	35107	15181	29524129
Prescribed underdose	101.75	15.85	80	35137	7706	29531604
Bone pain	89.26	15.85	110	35107	18342	29520968
Hypertension	87.32	15.85	321	34896	116293	29423017
Completed suicide	87.28	15.85	5	35212	90241	29449069
Incorrect dose administered	83.82	15.85	145	35072	32839	29506471
Blood potassium decreased	76.43	15.85	94	35123	15640	29523670
Therapy interrupted	74.41	15.85	69	35148	8317	29530993
Dysphagia	74.01	15.85	186	35031	54740	29484570
Spinal cord compression	72.48	15.85	48	35169	3534	29535776
Prostatic specific antigen abnormal	68.86	15.85	24	35193	406	29538904
Product dose omission issue	67.68	15.85	260	34957	96123	29443187
Decreased appetite	63.05	15.85	340	34877	145002	29394308
Oedema peripheral	62.87	15.85	267	34950	103290	29436020
Hepatic function abnormal	62.65	15.85	142	35075	39117	29500193
Acquired apparent mineralocorticoid excess	59.65	15.85	13	35204	28	29539282
Urinary tract obstruction	56.80	15.85	40	35177	3257	29536053
Pyrexia	53.84	15.85	170	35047	287452	29251858
Metastases to spine	53.57	15.85	33	35184	2143	29537167
Haematuria	47.88	15.85	138	35079	44001	29495309
Therapy change	45.87	15.85	32	35185	2566	29536744
Blood alkaline phosphatase increased	45.59	15.85	103	35114	28303	29511007
Chemotherapy	45.51	15.85	19	35198	535	29538775
Metastases to liver	45.38	15.85	63	35154	11793	29527517
Asthenia	44.61	15.85	421	34796	214829	29324481
Fluid retention	44.19	15.85	91	35126	23469	29515841
Apparent mineralocorticoid excess	43.27	15.85	10	35207	31	29539279
Drug hypersensitivity	42.87	15.85	14	35203	68392	29470918
Muscular weakness	42.37	15.85	166	35051	61886	29477424
Hydronephrosis	42.13	15.85	52	35165	8678	29530632
Back pain	42.09	15.85	236	34981	102048	29437262
Diabetes mellitus	40.77	15.85	122	35095	39709	29499601
Prostate cancer recurrent	39.29	15.85	20	35197	895	29538415
Oedema	38.64	15.85	121	35096	40362	29498948
Overdose	38.09	15.85	24	35193	79795	29459515
Acute coronary syndrome	37.79	15.85	59	35158	12266	29527044
Wrong technique in product usage process	37.76	15.85	102	35115	31326	29507984
Metastases to lymph nodes	37.48	15.85	34	35183	3983	29535327
Hypotension	36.20	15.85	115	35102	194239	29345071
Metastasis	35.93	15.85	31	35186	3398	29535912
Infusion related reaction	35.56	15.85	5	35212	43881	29495429
Liver function test abnormal	33.88	15.85	93	35124	28825	29510485
Cardiac failure	33.30	15.85	184	35033	79103	29460207
Pruritus	33.19	15.85	55	35162	116794	29422516
Fall	31.56	15.85	336	34881	176842	29362468
Condition aggravated	31.30	15.85	81	35136	146214	29393096
Metabolic acidosis	31.20	15.85	4	35213	37658	29501652
Plasma cell myeloma	30.61	15.85	4	35213	37111	29502199
Blood urine present	30.33	15.85	47	35170	9708	29529602
Prostatic specific antigen decreased	29.70	15.85	9	35208	95	29539215
Peripheral swelling	29.54	15.85	152	35065	63587	29475723
Bone lesion	29.47	15.85	25	35192	2679	29536631
Febrile neutropenia	29.03	15.85	56	35161	112184	29427126
Haemorrhage urinary tract	28.98	15.85	20	35197	1576	29537734
Aggression	28.91	15.85	4	35213	35537	29503773
Wheezing	28.86	15.85	3	35214	33237	29506073
Cystitis	28.70	15.85	42	35175	8250	29531060
Liver disorder	28.39	15.85	85	35132	27664	29511646
Haemorrhage subcutaneous	28.11	15.85	22	35195	2103	29537207
Intentional product misuse	27.96	15.85	4	35213	34657	29504653
Acute biphenotypic leukaemia	27.64	15.85	8	35209	71	29539239
Cardiac disorder	27.32	15.85	102	35115	37161	29502149
Anxiety	27.32	15.85	37	35180	85328	29453982
Asthma	27.09	15.85	4	35213	33845	29505465
Coma	26.67	15.85	7	35210	39443	29499867
Acquired haemophilia	26.57	15.85	15	35202	828	29538482
Agitation	26.50	15.85	14	35203	51290	29488020
Pelvic pain	26.38	15.85	21	35196	2058	29537252
Hypoxia	25.87	15.85	12	35205	47367	29491943
Metastases to soft tissue	25.84	15.85	10	35207	230	29539080
Suicidal ideation	25.80	15.85	5	35212	34711	29504599
Radiotherapy	25.42	15.85	11	35206	339	29538971
Intentional product use issue	24.42	15.85	10	35207	42488	29496822
Hypersensitivity	23.76	15.85	17	35200	52886	29486424
Injection site pain	23.43	15.85	5	35212	32441	29506869
Metastases to lung	23.25	15.85	37	35180	7818	29531492
Adverse drug reaction	23.10	15.85	72	35145	23948	29515362
Constipation	22.93	15.85	222	34995	113938	29425372
Bone cancer metastatic	22.44	15.85	8	35209	145	29539165
Neutropenia	22.40	15.85	81	35136	131630	29407680
Prostate cancer stage IV	21.58	15.85	12	35205	643	29538667
Hepatotoxicity	21.46	15.85	58	35159	17809	29521501
Lactic acidosis	21.16	15.85	5	35212	30242	29509068
Adrenal insufficiency	20.92	15.85	43	35174	11071	29528239
Lymphoedema	20.91	15.85	23	35194	3394	29535916
Oxygen saturation decreased	20.76	15.85	14	35203	44923	29494387
Depressed level of consciousness	20.73	15.85	9	35208	36933	29502377
Mucosal inflammation	20.62	15.85	6	35211	31589	29507721
Bradycardia	20.44	15.85	29	35188	65600	29473710
Staphylococcal infection	20.13	15.85	5	35212	29235	29510075
Retroperitoneal lymphadenopathy	19.97	15.85	12	35205	745	29538565
Anaemia	19.94	15.85	343	34874	200608	29338702
Therapeutic product effect incomplete	19.89	15.85	11	35206	39294	29500016
Blood creatinine increased	19.85	15.85	45	35172	85057	29454253
Hepatic enzyme increased	19.58	15.85	86	35131	33713	29505597
Urosepsis	19.55	15.85	41	35176	10705	29528605
Multiple organ dysfunction syndrome	19.54	15.85	28	35189	63088	29476222
Blood testosterone increased	19.41	15.85	13	35204	975	29538335
Cardio-respiratory arrest	19.35	15.85	19	35198	50582	29488728
Erythema	19.29	15.85	38	35179	75568	29463742
Transaminases increased	19.15	15.85	65	35152	22597	29516713
Rash	19.07	15.85	140	35077	189679	29349631
Drug reaction with eosinophilia and systemic symptoms	18.86	15.85	5	35212	27987	29511323
Coronary artery disease	18.82	15.85	15	35202	44175	29495135
Pollakiuria	18.43	15.85	53	35164	16863	29522447
Urinary retention	18.35	15.85	81	35136	31817	29507493
Sinusitis	18.29	15.85	9	35208	34341	29504969
White blood cell count increased	18.27	15.85	11	35206	37505	29501805
Groin pain	17.62	15.85	25	35192	4773	29534537
Angioedema	17.55	15.85	8	35209	31907	29507403
Alanine aminotransferase increased	17.33	15.85	144	35073	70800	29468510
Fracture	17.21	15.85	28	35189	6025	29533285
Free prostate-specific antigen increased	17.20	15.85	3	35214	0	29539310
Acute kidney injury	17.17	15.85	218	34999	265049	29274261
Tachycardia	17.12	15.85	38	35179	72372	29466938
Tremor	17.06	15.85	39	35178	73499	29465811
Blood creatine phosphokinase increased	17.05	15.85	14	35203	40630	29498680
Neuropathy peripheral	17.02	15.85	37	35180	70990	29468320
Liver function test increased	16.77	15.85	41	35176	11844	29527466
Hip fracture	16.77	15.85	38	35179	10454	29528856
Respiratory arrest	16.69	15.85	5	35212	25828	29513482
Cancer pain	16.49	15.85	17	35200	2330	29536980
Cardiac arrest	16.35	15.85	50	35167	85541	29453769
Investigation	16.09	15.85	11	35206	853	29538457
Hyperglycaemia	16.03	15.85	82	35135	34205	29505105

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Prostatic specific antigen increased	1960.13	16.88	489	23972	8271	64466000
Death	1289.89	16.88	1215	23246	481490	63992781
Disease progression	610.98	16.88	472	23989	141208	64333063
Hot flush	362.49	16.88	223	24238	46012	64428259
Therapy cessation	320.98	16.88	182	24279	32307	64441964
Hypokalaemia	293.66	16.88	292	24169	121611	64352660
Metastases to bone	287.85	16.88	145	24316	20290	64453981
Prostate cancer	268.72	16.88	137	24324	19658	64454613
Prostate cancer metastatic	262.24	16.88	82	24379	3222	64471049
Osteonecrosis of jaw	257.14	16.88	170	24291	39655	64434616
Hospitalisation	176.92	16.88	178	24283	75029	64399242
Fatigue	160.12	16.88	632	23829	748098	63726173
Product size issue	121.29	16.88	31	24430	575	64473696
Hospice care	104.09	16.88	53	24408	7572	64466699
Hormone-refractory prostate cancer	99.43	16.88	24	24437	348	64473923
Malignant neoplasm progression	95.37	16.88	161	24300	112710	64361561
Prescribed underdose	90.59	16.88	66	24395	17949	64456322
Urinary tract infection	90.57	16.88	241	24220	231355	64242916
Incorrect dose administered	78.94	16.88	106	24355	60659	64413612
Haematuria	77.81	16.88	105	24356	60366	64413905
Product use complaint	75.35	16.88	27	24434	1619	64472652
Decreased appetite	75.23	16.88	256	24205	281033	64193238
Toxicity to various agents	73.95	16.88	23	24438	363490	64110781
Completed suicide	66.07	16.88	5	24456	224409	64249862
Blood potassium decreased	62.72	16.88	77	24384	40322	64433949
Oedema peripheral	62.07	16.88	198	24263	210119	64264152
Prostate cancer recurrent	61.25	16.88	19	24442	726	64473545
Apparent mineralocorticoid excess	60.17	16.88	11	24450	34	64474237
Prostatic specific antigen abnormal	57.93	16.88	14	24447	204	64474067
Drug hypersensitivity	56.18	16.88	11	24450	237804	64236467
Metastases to spine	54.66	16.88	27	24434	3616	64470655
Asthenia	51.38	16.88	307	24154	427737	64046534
Cardiac failure	50.89	16.88	137	24324	132236	64342035
Acute coronary syndrome	47.73	16.88	47	24414	19263	64455008
Infusion related reaction	47.46	16.88	4	24457	164463	64309808
Bone pain	47.14	16.88	73	24388	47499	64426772
Urinary tract obstruction	46.48	16.88	25	24436	3992	64470279
Hydronephrosis	45.80	16.88	40	24421	14085	64460186
Hepatic function abnormal	45.58	16.88	85	24376	64228	64410043
Therapy interrupted	44.46	16.88	46	24415	19990	64454281
Acquired apparent mineralocorticoid excess	43.23	16.88	8	24453	27	64474244
Therapy change	42.78	16.88	28	24433	6406	64467865
Muscular weakness	42.29	16.88	125	24336	127213	64347058
Hypersensitivity	38.89	16.88	13	24448	196439	64277832
Product dose omission issue	37.70	16.88	160	24301	194587	64279684
Hypertension	37.04	16.88	195	24266	259066	64215205
Spinal cord compression	35.93	16.88	24	24437	5679	64468592
Haemorrhage urinary tract	35.31	16.88	17	24444	2152	64472119
Rhabdomyolysis	35.30	16.88	95	24366	91631	64382640
Metastases to lymph nodes	35.14	16.88	28	24433	8689	64465582
Arthropathy	34.73	16.88	3	24458	120964	64353307
Metastases to liver	34.54	16.88	44	24417	23897	64450374
Back pain	33.58	16.88	185	24276	249986	64224285
Urinary retention	32.36	16.88	63	24398	49138	64425133
Acute biphenotypic leukaemia	32.06	16.88	8	24453	134	64474137
Sinusitis	31.92	16.88	8	24453	145920	64328351
Constipation	31.72	16.88	171	24290	229166	64245105
Dehydration	31.61	16.88	164	24297	216599	64257672
Radiotherapy	31.51	16.88	10	24451	412	64473859
Blood urine present	30.16	16.88	36	24425	18304	64455967
Condition aggravated	29.16	16.88	61	24400	372365	64101906
Pruritus	29.07	16.88	46	24415	312354	64161917
Myocardial infarction	28.86	16.88	132	24329	165689	64308582
Dysphagia	28.28	16.88	97	24364	106715	64367556
Prostate cancer stage IV	27.82	16.88	10	24451	605	64473666
Metastases to lung	26.82	16.88	31	24430	15233	64459038
Prostatic specific antigen decreased	26.72	16.88	6	24455	62	64474209
Injection site pain	26.61	16.88	5	24456	111403	64362868
Atrial fibrillation	26.01	16.88	131	24330	170958	64303313
Asthma	25.67	16.88	3	24458	95222	64379049
Blood alkaline phosphatase increased	25.49	16.88	62	24399	56217	64418054
Fall	24.73	16.88	254	24207	416572	64057699
Acquired haemophilia	24.28	16.88	12	24449	1608	64472663
General physical health deterioration	24.04	16.88	146	24315	204279	64269992
Metastases to soft tissue	24.03	16.88	8	24453	384	64473887
Anxiety	23.83	16.88	25	24436	202624	64271647
Liver function test abnormal	23.33	16.88	62	24399	59339	64414932
Coma	23.03	16.88	3	24458	87612	64386659
Nasopharyngitis	22.16	16.88	25	24436	196048	64278223
Chemotherapy	22.10	16.88	11	24450	1496	64472775
Pollakiuria	21.50	16.88	41	24420	31489	64442782
Liver disorder	21.27	16.88	56	24405	53295	64420976
Alopecia	21.15	16.88	19	24442	165671	64308600
Diabetes mellitus	20.87	16.88	64	24397	66410	64407861
Wheezing	20.61	16.88	3	24458	80576	64393695
Toxic cataract	20.35	16.88	4	24457	20	64474251
Retroperitoneal lymphadenopathy	20.29	16.88	9	24452	945	64473326
Cancer pain	20.05	16.88	15	24446	4242	64470029
Haemorrhage subcutaneous	19.73	16.88	15	24446	4346	64469925
Oedema	19.71	16.88	78	24383	91857	64382414
Bone lesion	19.64	16.88	16	24445	5121	64469150
Exposure during pregnancy	19.62	16.88	3	24458	77672	64396599
Depressed level of consciousness	18.72	16.88	4	24457	81432	64392839
Blood testosterone increased	18.62	16.88	8	24453	778	64473493
Therapeutic product effect incomplete	18.54	16.88	8	24453	103474	64370797
Overdose	18.41	16.88	20	24441	159546	64314725
Anaemia	18.00	16.88	221	24240	378459	64095812
Urosepsis	17.95	16.88	31	24430	22063	64452208
Intentional product misuse	17.79	16.88	3	24458	72292	64401979
Intentional product use issue	17.69	16.88	7	24454	95357	64378914
Pyrexia	17.54	16.88	132	24329	558512	63915759
Alanine aminotransferase increased	17.42	16.88	101	24360	138930	64335341
Lymphoedema	17.21	16.88	20	24441	9885	64464386
Polyneuropathy in malignant disease	17.12	16.88	5	24456	155	64474116
Wound	17.09	16.88	4	24457	76473	64397798
Rash	17.06	16.88	103	24358	458446	64015825
Blood glucose increased	16.99	16.88	78	24383	97995	64376276

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L02BX03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONE ANTAGONISTS AND RELATED AGENTS Other hormone antagonists and related agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D065088	Steroid Synthesis Inhibitors
FDA MoA	N0000182137	Cytochrome P450 2D6 Inhibitors
FDA MoA	N0000182632	Cytochrome P450 17A1 Inhibitors
FDA EPC	N0000182633	Cytochrome P450 17A1 Inhibitor
FDA MoA	N0000187062	Cytochrome P450 2C8 Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:50266	Prodrugs
CHEBI has role	CHEBI:68640	17-alpha-hydroxylase/C17,20-lyase inhibitors

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Malignant tumor of prostate	indication	399068003	DOID:10283
Metastatic castration-resistant prostate cancer	indication	427492003
Hyperbilirubinemia	contraindication	14783006	DOID:2741
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypokalemia	contraindication	43339004
Body fluid retention	contraindication	43498006
Chronic heart failure	contraindication	48447003
Liver function tests abnormal	contraindication	166603001
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.68	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
125MG	YONSA	SUN PHARM	N210308	May 22, 2018	RX	TABLET	ORAL	10292990	May 20, 2034	USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Steroid 17-alpha-hydroxylase/17,20 lyase	Enzyme	P05093	CP17A_HUMAN	INHIBITOR	IC50	8.54	CHEMBL	IUPHAR
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	5.57	CHEMBL
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN		EC50	4.77	CHEMBL
Cytochrome P450 11B1, mitochondrial	Enzyme	P15538	C11B1_HUMAN		IC50	5.79	CHEMBL
Cytochrome P450 11B2, mitochondrial	Enzyme	P19099	C11B2_HUMAN		IC50	5.76	CHEMBL
Cytochrome P450 17A1	Enzyme		CP17A_RAT		IC50	7.90	CHEMBL

External reference:

ID	Source
4030721	VUID
N0000182731	NUI
D09701	KEGG_DRUG
4030720	VANDF
4030721	VANDF
C2607886	UMLSCUI
CHEBI:68639	CHEBI
CHEBI:68642	CHEBI
AER	PDB_CHEM_ID
CHEMBL271227	ChEMBL_ID
CHEMBL254328	ChEMBL_ID
D000069501	MESH_DESCRIPTOR_UI
9288	IUPHAR_LIGAND_ID
C089740	MESH_SUPPLEMENTAL_RECORD_UI
6745	IUPHAR_LIGAND_ID
154229-19-3	SECONDARY_CAS_RN
EM5OCB9YJ6	UNII
9821849	PUBCHEM_CID
132971	PUBCHEM_CID
DB05812	DRUGBANK_ID
1100071	RXNORM
181225	MMSL
27860	MMSL
299803	MMSL
d07766	MMSL
013720	NDDF
013721	NDDF
699678007	SNOMEDCT_US
699679004	SNOMEDCT_US
767857007	SNOMEDCT_US
C0754011	UMLSCUI
7375	INN_ID
G819A456D0	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1125	TABLET, FILM COATED	250 mg	ORAL	ANDA	27 sections
Abiraterone	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9597	TABLET	250 mg	ORAL	ANDA	26 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6920	TABLET	250 mg	ORAL	ANDA	29 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6920	TABLET	250 mg	ORAL	ANDA	29 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6921	TABLET, FILM COATED	500 mg	ORAL	ANDA	29 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6921	TABLET, FILM COATED	500 mg	ORAL	ANDA	29 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6924	TABLET, FILM COATED	250 mg	ORAL	ANDA	29 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6948	TABLET	250 mg	ORAL	ANDA	28 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	16714-963	TABLET	250 mg	ORAL	ANDA	27 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-024	TABLET	250 mg	ORAL	ANDA	27 sections
ABIRATERONE ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-073	TABLET	500 mg	ORAL	ANDA	27 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	42292-057	TABLET	250 mg	ORAL	ANDA	29 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	43598-358	TABLET	250 mg	ORAL	ANDA	27 sections
YONSA	HUMAN PRESCRIPTION DRUG LABEL	1	47335-401	TABLET	125 mg	ORAL	NDA	28 sections
YONSA	HUMAN PRESCRIPTION DRUG LABEL	1	47335-401	TABLET	125 mg	ORAL	NDA	28 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-181	TABLET	250 mg	ORAL	ANDA	29 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-181	TABLET	250 mg	ORAL	ANDA	29 sections
Zytiga	HUMAN PRESCRIPTION DRUG LABEL	1	57894-150	TABLET	250 mg	ORAL	NDA	32 sections
Abiraterone acetate	HUMAN PRESCRIPTION DRUG LABEL	1	57894-155	TABLET	250 mg	ORAL	NDA AUTHORIZED GENERIC	31 sections
Zytiga	HUMAN PRESCRIPTION DRUG LABEL	1	57894-195	TABLET, FILM COATED	500 mg	ORAL	NDA	32 sections
Abiraterone acetate	HUMAN PRESCRIPTION DRUG LABEL	1	57894-199	TABLET, FILM COATED	500 mg	ORAL	NDA	31 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-4327	TABLET	250 mg	ORAL	ANDA	28 sections
abiraterone acetate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-4764	TABLET, FILM COATED	500 mg	ORAL	ANDA	32 sections
Abiraterone Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	60687-455	TABLET	250 mg	ORAL	ANDA	29 sections
Abiraterone acetate	HUMAN PRESCRIPTION DRUG LABEL	1	64679-021	TABLET	250 mg	ORAL	ANDA	26 sections
Abiraterone acetate	Human Prescription Drug Label	1	64980-418	TABLET	250 mg	ORAL	ANDA	25 sections
Abiraterone	HUMAN PRESCRIPTION DRUG LABEL	1	68001-489	TABLET	250 mg	ORAL	ANDA	25 sections
abiraterone acetate	HUMAN PRESCRIPTION DRUG LABEL	1	68462-135	TABLET	250 mg	ORAL	ANDA	30 sections
abiraterone acetate	HUMAN PRESCRIPTION DRUG LABEL	1	68462-135	TABLET	250 mg	ORAL	ANDA	30 sections
abiraterone acetate	HUMAN PRESCRIPTION DRUG LABEL	1	68462-882	TABLET	500 mg	ORAL	ANDA	30 sections